ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Vividion scores major financing round

by Lisa M. Jarvis
May 2, 2019 | APPEARED IN VOLUME 97, ISSUE 18

 

09718-buscon17-vividioncxd.jpg
Credit: Vividion
Vividion's labs in San Diego

Vividion Therapeutics has raised $82 million in its second major round of financing, which included both new and old investors. Founded in 2014 based on technology from Scripps Research Institute professors Benjamin Cravatt, Phil Baran, and Jin-Quan Yu, Vividion uses chemical probes to map out the hidden pockets on difficult-to-drug proteins linked to cancer and inflammation. With this latest funding round, the company has more than $165 million in cash to pursue a pipeline of direct and allosteric inhibitors and targeted protein degraders.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment